Journal
MAYO CLINIC PROCEEDINGS
Volume 97, Issue 1, Pages 124-133Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.mayocp.2021.09.007
Keywords
-
Categories
Funding
- US National Institutes of Health [P01 CA87969, UM1 CA186107, P01 CA55075, UM1 CA167552, U01 CA167552, P50 CA127003, R01 CA118553, R01 CA169141, R01 CA137178, K24 DK098311, R35 CA197735, R01 CA151993, R01 CA248857, R00 CA215314, K07 CA188126]
- Nodal Award from the Dana-Farber Harvard Cancer Center [2016-02]
- Stand Up to Cancer Colorectal Cancer Dream Team Translational Research Grant [SU2C-AACR-DT22-17]
- American Cancer Society Mentored Research Scholar Grant [MRSG-17-220-01-NEC]
- Project P Fund
- Friends of the Dana-Farber Cancer Institute
- Bennett Family Fund
- Entertainment Industry Foundation through National Colorectal Cancer Research Alliance
- Uehara Memorial Foundation
- Mitsukoshi Health and Welfare Foundation
- Yasuda Medical Foundation
- Australia Awardse-Endeavour Scholarships and Fellowships Program
- Conquer Cancer Foundation of ASCO Career Development Award
- Douglas Gray Woodruff Chair fund
- Guo Shu Shi Fund
- Anonymous Family Fund for Innovations in Colorectal Cancer
- George Stone Family Foundation
- Overseas Research Fellowship [201860083, 201960541]
Ask authors/readers for more resources
This study examined the association between coffee intake in colorectal cancer patients and survival. It was found that the correlation between coffee intake and colorectal cancer-specific mortality differed according to Crohn disease-like lymphoid reaction.
Given previous biologic evidence of immunomodulatory effects of coffee, we hypothesized that the association between coffee intake of colorectal cancer patients and survival differs by immune re-sponses. Using a molecular pathologic epidemiology database of 4465 incident colorectal cancer cases, including 1262 cases with molecular data, in the Nurses' Health Study and the Health Professionals Follow-up Study, we examined the association between coffee intake of colorectal cancer patients and survival in strata of levels of histopathologic lymphocytic reaction and T-cell infiltrates in tumor tissue. We did not observe a significant association of coffee intake with colorectal cancer-specific mortality (multivariable-adjusted hazard ratio [HR] for 1-cup increase of coffee intake per day, 0.93; 95% CI, 0.84 to 1.03). Although statistical significance was not reached at the stringent level (alpha=.005), the association of coffee intake with colorectal cancer-specific mortality differed by Crohn disease-like lymphoid reaction (P-interaction=.007). Coffee intake was associated with lower colorectal cancer-specific mortality in patients with high Crohn disease-like reaction (multivariable HR for 1-cup increase of coffee intake per day, 0.55; 95% CI, 0.37 to 0.81; P-trend=.002) but not in patients with intermediate Crohn disease-like reaction (the corresponding HR, 1.02; 95% CI, 0.72 to 1.44) or negative/low Crohn disease-like reaction (the corresponding HR, 0.95; 95% CI, 0.83 to 1.07). The associations of coffee intake with colorectal cancer-specific mortality did not significantly differ by levels of other lymphocytic reaction or any T-cell subset (P-interaction>.18). There is suggestive evidence for differential prognostic effects of coffee intake by Crohn disease-like lymphoid reaction in colo-rectal cancer. (C) 2021 Mayo Foundation for Medical Education and Research
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available